UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | March 14, 2006 |
Lifeline Therapeutics, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
| Colorado | 000-30489 | 84-1097796 |
|
_____________________ (State or other jurisdiction |
_____________ (Commission |
______________ (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| 6400 S. Fiddler's Green Circle, Suite 1970, Englewood, Colorado | 80111 | |
|
_________________________________ (Address of principal executive offices) |
___________ (Zip Code) |
| Registrant’s telephone number, including area code: | 720-488-1711 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On March 14, 2006, Lifeline Therapeutics, Inc. issued a press release entitled "Dr. Sally K. Nelson of Lifeline Therapeutics, Inc. to Present at OCC Congress 2006." The press release is attached hereto as Exhibit 99.1
Item 9.01 Financial Statements and Exhibits.
99.1 Press Release dated March 14, 2006, entitled "Dr. Sally K. Nelson of Lifeline Therapeutics, Inc. to Present at OCC Congress 2006."
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Lifeline Therapeutics, Inc. | ||||
| March 16, 2006 | By: |
Stephen K. Onody
|
||
|
|
||||
| Name: Stephen K. Onody | ||||
| Title: CEO | ||||
Exhibit Index
| Exhibit No. | Description | |
|
|
|
|
|
99.1
|
Press release dated March 14, 2006, entitled "Dr. Sally K. Nelson of Lifeline Therapeutics, Inc. to Present at OCC Congress 2006" |
FOR IMMEDIATE RELEASE NEWS
March 14, 2006 OTCBB: LFLT
DR. SALLY K. NELSON OF LIFELINE THERAPEUTICS, INC.
TO PRESENT AT OCC CONGRESS 2006
DENVER, Colorado — Lifeline Therapeutics, Inc. (OTCBB: LFLT), maker of Protandim®, today announced that Dr. Sally Nelson will present a scientific poster at the OCC Congress 2006 in Santa Barbara, California, March 15 — 18, 2006. The congress is the XIIth Annual Meeting of the Oxygen Club of California (OCC) on Oxidants and Antioxidants in Biology.
OCC is a scientific organization dedicated to enhancing interactions and providing meetings and discussion forums worldwide to those interested in free radicals in biological systems, oxidants and antioxidants in biology and medicine, micronutrients, nutrition and health.
Dr. Nelson, recently named the Company’s Science Coordinator, is also a co-author of “The induction of human superoxide dismutase and catalase in vivo: A fundamentally new approach to antioxidant therapy” published in the scientific journal Free Radical Biology & Medicine (Jan. 15, 2006). The human study demonstrated Protandim® was able to significantly reduce oxidative stress in men and women. Oxidative stress results when the balance between oxidants and antioxidant enzymes is upset. Oxidative stress, which many authorities believe is central to the cellular aging process, increases as we age. Furthermore, there are over a thousand scientific research studies indicating that high oxidative stress is associated with various diseases.
About Sally Nelson, PhD
Dr. Nelson is an Associate Clinical Professor in the Department of Pulmonary and Critical Care Medicine at the University of Colorado at Denver and Health Sciences Center, Denver, Colorado. Dr. Nelson recently became the Company’s Science Coordinator and is a shareholder in the Company.
About Lifeline Therapeutics
Lifeline Therapeutics, Inc. markets Protandim®, a patent-pending dietary supplement that increases the body’s natural antioxidant protection. Lifeline Therapeutics is committed to helping people achieve health and wellness for life. For more information, please visit the Protandim® product website at http://www.protandim.com.
Oxidative stress (cell damage caused by free radicals) occurs as a person ages or is subjected to stresses such as certain illnesses. TBARS are harmful, reactive substances that indicate the level of oxidative stress in the body. New data from a scientific study in men and women show that after 30 days of taking Protandim®, the level of circulating TBARS decreased an average of 40 percent, and the age-related increase in TBARS was eliminated. Protandim® strengthens a person’s defenses against oxidative stress by increasing the body’s natural activity of antioxidant enzymes.
Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable common law. These statements involve known and unknown risks and uncertainties that may cause the Company’s actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company’s control. Other important factors that the Company believes might cause such differences include the Company’s limited cash flow and the rapid development of technology, lack of liquidity for the Company’s common stock, working capital shortages, the length of time for scientific advances to reach the market (if they ever reach the market), among other risks. In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company’s filings with the Securities and Exchange Commission.
CONTACT:
Lifeline Therapeutics, Inc.
Stephen K. Onody, CEO Telephone: 720-488-1711
Gerald J. Houston, CFO Fax: 303-565-8700